Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Patients turned to compound versions, which were made by licensed pharmacists but were not FDA approved. Last year, around ...

At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...

Larger outsourcing pharmacies making compound versions of Zepbound have until March 19 to stop, according to the FDA. State-licensed pharmacies must stop making most compounded semaglutide (copies ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists ...

Terpenes from cannabis may relieve chronic pain without THC’s psychoactive effects. Researchers found that certain terpenes ...